{
"id":"mk19_a_id_t36",
"number":36,
"bookId":"id",
"title":{
"__html":"Select Medications Causing Secondary Immunodeficiency Disorders and Preventive Measures<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"9b7279",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 36. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_a_id_t36"
}
]
},
"Select Medications Causing Secondary Immunodeficiency Disorders and Preventive Measures",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"353bd6",
"class":"col hd l",
"children":[
"Medication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1b1583",
"class":"col hd l",
"children":[
"Indication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e8cda5",
"class":"col hd l",
"children":[
"Pathogens"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90087c",
"class":"col hd l",
"children":[
"Prevention or Management"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"78727f",
"class":"cell txt l",
"children":[
"Tumor necrosis factor-α inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9573f9",
"class":"cell txt li",
"children":[
"Inflammatory bowel disease, inflammatory arthritis, psoriasis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eb67f8",
"class":"cell txt l",
"children":[
"Mycobacterial, fungal (",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Histoplasma"
]
},
", ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Coccidioides"
]
},
"), reactivation of hepatitis B"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"75e52d",
"class":"cell txt l",
"children":[
"Screen for hepatitis B and C viruses before initiation; screen for tuberculosis before initiation and if a tuberculosis exposure occurs"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2449bd",
"class":"cell txt l",
"children":[
"Natalizumab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e06f32",
"class":"cell txt li",
"children":[
"Multiple sclerosis, Crohn disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"119e9c",
"class":"cell txt l",
"children":[
"JC virus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"869a3a",
"class":"cell txt l",
"children":[
"Screen for seropositivity at baseline, with repeat testing and brain MRI based on serostatus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"72a34b",
"class":"cell txt l",
"children":[
"Eculizumab",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9fe32",
"class":"cell txt l",
"children":[
"Hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a1c02",
"class":"cell txt l",
"children":[
" ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Neisseria meningitidis"
]
},
" "
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9d3566",
"class":"cell txt l",
"children":[
"Immunization with quadrivalent and serogroup B meningococcal vaccines 2 weeks before initiation, prophylactic penicillin"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fad6a2",
"class":"cell txt l",
"children":[
"Rituximab"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ae531d",
"class":"cell txt l",
"children":[
"B-cell malignancies, autoimmune diseases"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"16696b",
"class":"cell txt l",
"children":[
"JC virus, reactivation of chronic hepatitis B, cytomegalovirus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d4e054",
"class":"cell txt l",
"children":[
"Screen for hepatitis B with treatment of antigen-positive patients and consideration of treatment for previously infected antigen-negative patients"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"adb71f",
"class":"cell txt l",
"children":[
"Glucocorticoids"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"629daa",
"class":"cell txt l",
"children":[
"Multiple uses"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c6f9a5",
"class":"cell txt l",
"children":[
"Hepatitis B, herpes zoster, ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Strongyloides"
]
},
" (reactivation); ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis jirovecii"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1a041d",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Pneumocystis"
]
},
" prophylaxis for patients with >1 month of glucocorticoid use at dose equivalent to >20 mg of prednisone"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
" ",
{
"type":"cross-reference",
"target":"mk19_b_rm_s2",
"children":[
"MKSAP 19 Rheumatology"
]
},
" includes further information on some medications mentioned in this table."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Terminal complement inhibitor, conferring up to a 2000-fold increased risk of meningococcal disease."
]
]
}